Double-blind, Randomized, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Ravulizumab Administered Intravenously In Adult Participants At High Risk Of Delayed Graft Function After Kidney Transplantation

Overview

About this study

The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • ≥ 18 years of age at the time of signing the informed consent

  • Diagnosed with Dialysis-dependent End-Stage Kidney Disease (ESKD)

  • A candidate for kidney transplant from:

    1. Donation after Circulatory Death (DCD) donor

    2. High-risk Donation after Brain Death (DBD) donor

Exclusion Criteria:

  • Is to receive a kidney from a donor with category I,II,IV and V Maastricht Classification

  • Diagnosed with Acute Kidney Injury (AKI) of Stage 3 severity according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

 

Eligibility last updated 07/22/2025. Questions regarding updates should be directed to the study team contact.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Hani Wadei, M.D.

Contact us for the latest status

Contact information:

Christian Glover

(904) 953-3302

Glover.Christian@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Girish Mour, M.B.B.S.

Contact us for the latest status

Contact information:

Hannah Samuel Gnanadas

(480) 342-2906

SamuelGnanadas.Hannah@mayo.edu

More information

Publications

Publications are currently not available